| Bioactivity | SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases[1]. |
| Invitro | SLC3037 (1-10 μM, 5 h) 对脂多糖和 MSU 诱导的 BMDMs IL-1β 有剂量依赖性抑制作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SLC3037 相关抗体: |
| Formula | C29H35N7OS |
| Molar Mass | 529.70 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Park K, et al. A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout. Front Immunol. 2024 Feb 2;14:1307739. |